Memory T Lymphocytes in Cancer Immunology (R01)
National Institutes of Health · Opportunity PA-07-255
Multiple Receipt Dates - See Link to Full Announcement for details.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities
- Native American tribal organizations (other)
- Nonprofits with 501(c)(3), other than higher education
- Nonprofits without 501(c)(3)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
About this opportunity
-Purpose. This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits applications from organizations that propose to conduct basic research studies that are relevant to antitumor immunity and that are focused on memory T lymphocytes and/or the cells and molecules that interact with memory T lymphocytes. Such research may include investigations of T memory cell differentiation, maintenance, and reactivation. Investigations may entail both human and animal studies, and both in vitro and in vivo analyses. Innovative uses of existing technologies and reagents, as well as the development of new technologies and reagents, are encouraged. We anticipate that the results of such research will ultimately improve the prospects for successful cancer immunotherapies and cancer vaccine development. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-06-349, that solicits applications under the Exploratory/Developmental Grant (R21) award mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) | National Institutes of Health | August 18, 2026 23d left | — | Nonprofits |
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2026 43d left | $499k | Nonprofits |
| Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2026 43d left | — | Nonprofits |
| Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed) | National Institutes of Health | September 7, 2026 43d left | — | Nonprofits |